PET Imaging of CXCR4 Expression Using [18F] AlF-NOTA-QHY-04 for Solid Tumors and Hematologic Malignancy

S Xu, J Liu, J Yu - 2024 - Soc Nuclear Med
242481 Introduction: CXC motif chemokine receptor 4 (CXCR4) is an important target for the
diagnosis and treatment of a variety of cancers. Here, we aimed to develop a new CXCR4 …

Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging

MA Spahn, K Luyten, T Van Loy, M Sathekge… - Nuclear Medicine and …, 2024 - Elsevier
Background The CXC chemokine receptor type 4 (CXCR4) is overexpressed in many
cancers, eg multiple myeloma and acute leukemia, yet solely [68 Ga] PentixaFor is used for …

CXCR4-targeted PET imaging of central nervous system B-cell lymphoma

P Herhaus, J Lipkova, F Lammer… - Journal of Nuclear …, 2020 - Soc Nuclear Med
CXC chemokine receptor 4 (CXCR4) is a transmembrane chemokine receptor involved in
growth, survival, and dissemination of cancer, including aggressive B-cell lymphoma. MRI is …

PET imaging of tumor CXCR4 expression with 18F-T140

O Jacobson, I Weiss, J Farber, X Chen - 2010 - Soc Nuclear Med
282 Objectives Expression of the chemokine receptor CXCR4 by cancers has been shown
to correlate with the aggressive biological behavior, including increased rates of cell …

First experience with chemokine receptor CXCR4–targeted PET imaging of patients with solid cancers

T Vag, C Gerngross, P Herhaus, M Eiber… - Journal of Nuclear …, 2016 - Soc Nuclear Med
CXCR4 is a chemokine receptor that is overexpressed in various human cancers and is
involved in tumor metastasis. The aim of this proof-of-concept study was to evaluate a novel …

CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology

N Dreher, S Hahner, CT Fuß, W Schlötelburg… - European Journal of …, 2024 - Springer
Background CXC motif chemokine receptor 4 (CXCR4) is overexpressed in various solid
cancers and can be targeted by CXCR4-directed molecular imaging. We aimed to …

[18F] Trifluoroborate-based CXCR4-targeting PET Agents Based on a Potent and Novel Pharmacophore

D Kwon, Z Zhang, J Lozada, R Tan, R Wilson, N Colpo… - 2022 - Soc Nuclear Med
2579 Introduction: CXC Chemokine Receptor 4 (CXCR4) is highly expressed in many
malignancies and plays key roles in tumorigenicity and metastasis, correlating with …

Imaging of CXC motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET

AK Buck, A Haug, N Dreher, A Lambertini… - Journal of Nuclear …, 2022 - Soc Nuclear Med
In recent years, molecular imaging addressing the CXC motif chemokine receptor 4
(CXCR4) has increasingly been used in various clinical settings. Here, we aimed to assess …

PET of tumor CXCR4 expression with 4-18F-T140

O Jacobson, ID Weiss, DO Kiesewetter… - Journal of Nuclear …, 2010 - Soc Nuclear Med
Expression of the chemokine receptor CXCR4 by cancers has been shown to correlate with
tumor aggressiveness and poor prognosis and may also contribute to metastatic seeding of …

Novel peptide-based PET probe for non-invasive imaging of CXC chemokine receptor type 4 (CXCR4) in tumors

AM Trotta, M Aurilio, C D'Alterio, C Ierano… - Journal of Medicinal …, 2021 - ACS Publications
The recently reported CXCR4 antagonist 3 (Ac-Arg-Ala-[DCys-Arg-2Nal-His-Pen]-CO2H)
was investigated as a molecular scaffold for a CXCR4-targeted positron emission …